리커너스_베이직

• LN Robotics' catheter control robot "AVIAR" receives innovative medical technology recognition for percutaneous coronary intervention (PCI).
• The AVIAR robot allows precise control of surgical tools in 1mm increments and reduces radiation exposure to medical professionals by up to 84%.
• Recognized for its potential to improve clinical effectiveness and safety, the technology will undergo clinical trials over the next three years to gather patient data.

AI and medical robotics company LN Robotics (co-CEOs Jaesoon Choi and Donghee Kim) announced that its catheter control robot for percutaneous coronary intervention (PCI) has been designated as an innovative medical technology by the Ministry of Health and Welfare.

The innovative medical technology evaluation system was introduced in 2019, facilitates the rapid adoption of high-demand medical technologies in clinical settings. If a new technology demonstrates potential effectiveness and safety, it can enter the medical field conditionally, even before securing full clinical validation. Following this period, the technology undergoes a reevaluation to be officially included in the national health insurance coverage.

The PCI procedure utilizing the catheter control robot "AVIAR" is the first of its kind developed in South Korea by LN Robotics. The coronary arteries, which supply blood to the heart muscle, can become narrowed due to various factors such as hypertension, diabetes, and hyperlipidemia, leading to conditions like angina and myocardial infarction. To treat these conditions, percutaneous coronary interventions, including balloon angioplasty, are performed. Using AVIAR, medical professionals can achieve precise control of surgical tools in 1mm increments and significantly reduce radiation exposure by up to 84%.

Unlike competing cardiovascular robotics systems, AVIAR is designed for a broad range of procedures, including complex surgeries. Its key differentiators include a multi-channel tool control system and a haptic feedback mechanism that enhances the precision and reliability of surgical tool manipulation.

With the innovative medical technology designation, the use of AVIAR will be permitted for up to three years—from July 2025 to June 2028—in general and tertiary hospitals under non-reimbursed or selective reimbursement conditions.

A spokesperson from LN Robotics stated, "There have been few cases of robotic technologies receiving innovative medical technology designations. This recognition highlights the significant potential of AVIAR for safe and effective coronary interventions. We are committed to gathering robust patient-centric clinical data to pass the new medical technology evaluation and contribute to improving cardiovascular health worldwide."

In February 2023, AVIAR became the first coronary intervention robot to receive approval from South Korea’s Ministry of Food and Drug Safety. Since then, it has been undergoing clinical trials at several university hospitals. In December 2023, the technology also became the first surgical robot-related technology to receive the Health New Technology (NET) certification from the Ministry of Health and Welfare.

#LNRobotics #robotics #AVIAR #혁신의료기술 #innovativemedicaltechnology